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PURPOSE. Endothelial cell density (ECD) is the principal factor determining the success of
corneal transplants. Here we explored a strategy to increase corneal ECD in human explants
via modulation of the ZO-1/ZONAB pathway. In multiple cell types, ZO-1 maintains G1 cell
cycle arrest via cytoplasmic sequestration of the mitosis-inducing transcription factor ZONAB.
In this study, we assessed the effects of lentiviral vector-mediated downregulation of ZO-1 or
overexpression of ZONAB upon ECD and the integrity of the endothelial monolayer.
METHODS. HIV-based lentiviral vectors were used to deliver either constitutively expressed
ZONAB (LNT-ZONAB), or a small hairpin RNA targeting ZO-1 (LNT-shZO1). Human corneal
specimens were bisected and each half was exposed to either treatment or control vector.
After 1 week in ex vivo culture, effects were assessed by quantitative RT-PCR,
immunohistochemistry, and ECD assessment.
RESULTS. LNT-shZO1 achieved an ~45% knockdown of ZO-1 mRNA in corneal endothelial cells
cultured ex vivo, reduced ZO-1 staining, and did not affect morphologic endothelial monolayer
integrity. The proliferative effect of LNT-shZO1 correlated with control ECD but not with donor
age. Within a low-ECD cohort an ~30% increase in ECD was observed. LNT-ZONAB achieved a
>200-fold overexpression of ZONAB mRNA, which led to an ~25% increase in ECD.
CONCLUSIONS. ZO-1 downregulation or ZONAB upregulation increases corneal ECD via
interference with contact inhibition and cell cycle control. With further development, such
approaches might provide a means for improving ECD in donor corneas before
transplantation.
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Corneal transplantation is the most common form oftransplantation surgery undertaken with approximately
3500 grafts performed annually in the United Kingdom,1 75,000
in the United States,2 and 185,000 globally.3 Endothelial disease
that results in cellular decompensation and an associated loss of
corneal transparency is a major indication for corneal
transplantation,2,4 and posttransplantation endothelial decom-
pensation represents a major cause of eventual graft failure.5,6
This argues for strict selection of donor corneas on the basis of
a sufficiently high endothelial cell density (ECD). However, in
many countries such selection has led to a shortage of donor
corneas deemed suitable for transplantation. The increasing
average age of tissue donors contributes further to lowering
average ECD7 in donated corneas. A further decline in the ECD
of donor material is associated with extended storage in organ
culture.8,9 In UK eye banks the number of corneas deemed
unsuitable for transplantation increased from 17% to 33% after
28 days of storage.8 Finally, transplantation surgery itself can
result in endothelial cells losses of up to 23%.10
In humans, corneal endothelial cells do not divide at a
sufficient rate to replace lost cells. After complete formation of
the endothelial monolayer at birth, a constant cell loss can be
observed throughout life. Histologic and in vivo confocal
microscopy studies indicate that the average rate of cell loss is
0.3% to 0.6% per year in normal subjects throughout adult life,
and is 10-fold higher after a corneal transplant.11–14 Several
mechanisms of active repression of corneal endothelial cell
reentry to the cell cycle have been identified: (1) a lack of
response to positive growth factors, (2) the antiproliferative
effect of TGF-b2 in the aqueous humor, and (3) contact
inhibition though mature cell-cell junctions.15–17 Contact inhibi-
tion, that is, the presence of mature cell–cell junctions, is
considered the most important factor inhibiting endothelial
proliferation in vivo.18 Release of cells from their confluent
monolayer to create a single cell suspension is the principal
requirement for culturing primary corneal endothelial cells in
vitro. Mitotic inhibition in vivo has been investigated in rats,
where corneal endothelial cells continue to mature after birth.19
Proliferation of endothelial cells does not cease until stable cell-
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cell contacts, represented by connexin-43 and ZO-1 expression,
and cell-substrate contacts, represented by an organized pattern
of fibronectin and collagen IV, are established. Senoo et al.20
have attempted to disrupt the endothelial monolayer of human
corneal samples ex vivo by using EDTA, and assessed
proliferation by Ki67 immunostaining. EDTA disruption alone
is not sufficient to induce proliferation, nor is incubation in
mitogen-containing medium. A combination of EDTA-mediated
contact disruption and mitogenic factors do promote prolifer-
ation, but this method does not increase total ECD.21
The ZO-1/ZONAB pathway has been identified as a key
molecular pathway controlling contact inhibition.22,23 ZO-1, a
membrane protein located at the intracellular side of tight
junctions (but that is not essential to their assembly24), binds a Y-
box transcription factor, ZO-1–associated nucleic acid binding
protein (ZONAB). Subcellular localization of ZONAB determines
its activity as a transcription factor. In confluent cells containing
many tight junctions, ZONAB is bound to the SH3 domain of ZO-
1. If, however, low cell density prevents the establishment of
tight junctions, ZONAB is released from its binding partner and
is free to accumulate within the nucleus. Here it acts as a
repressor of the erb-2 gene, a tyrosine kinase coreceptor
regulating epithelial differentiation.23 Furthermore, free ZONAB
associates with cell division kinase 4 (CDK4), a central regulator
of the cell cycle. By facilitating nuclear accumulation of CDK4,
ZONAB promotes S phase entry.22 ZONAB also acts as a
transcription factor directly regulating the expression of
proliferating cell nuclear antigen (PCNA), encoding a crucial
component of the DNA replication machinery, and Cyclin D1, a
key regulator of G1/S-phase transition.25 These mechanisms lead
to proliferation and eventually increased cell density with
formation of tight junctions. By sequestering ZONAB at the tight
junctions, ZO-1 reduces cell proliferation in a cell density–
dependent manner (Supplementary Fig. S1). This concept has
been investigated in vitro in MDCK and MCF-10A cells,
mammalian epithelial cells derived from the kidney and
mammary gland, respectively. Overexpression of ZO-1 reduces
proliferation, while overexpression of ZONAB increases cell
density even in mature monolayers.22,25 We have also investi-
gated this signalling pathway in vivo, in the retinal pigment
epithelium of mice.26 Both overexpression of ZONAB or
knockdown of ZO-1 promotes RPE proliferation. Modulation
of the ZO-1/ZONAB pathway may therefore provide an effective
strategy to overcome contact inhibition and induce cell
proliferation in corneal endothelial cells. In this study, we
assessed the effects of lentiviral vector-mediated knockdown of
ZO-1 or overexpression of ZONAB on the proliferation of
corneal endothelial cells in excised human corneas, analyzing
the change in ECD as the primary outcome measure.
METHODS
Recombinant Lentiviral Vectors
Second-generation, self-inactivating HIV-based lentiviral vectors
pseudotyped with vesicular stomatitis virus G glycoprotein
(VSV-G) were produced by transient transfection of three
plasmids into HEK-293T cells as previously described.27,28 The
pHR’SIN plasmid backbone was used as transfer vector
delivering either ZONAB or hrGFP under the ubiquitous active
spleen focus-forming virus (SFFV) promoter, as described
previously.25 For knockdown, a small hairpin targeting ZO-1
was first cloned into the mU6pro plasmid and then transferred
into the pHR’SIN plasmid. The sense strand of the targeting
hairpins26 was 50-AAGATAGTTTGGCAGCAAGAG-30. Vector in
cell culture supernatant was purified by filtration (0.45-lm
filter), concentrated by ultracentrifugation (65,000g for 105
minutes), and resuspended in OptiMEM (Invitrogen, Paisley,
UK), yielding vector concentrated to 108 to 109 infectious
particles per milliliter.
Corneal Samples
Two sources of human corneal samples were used.
1. Whole human corneas from deceased multiorgan do-
nors, unsuitable for transplantation owing to reasons
unrelated to endothelial function, were obtained from
Moorfields Eye Bank, London, United Kingdom, after
consent for use in research was obtained from relatives.
These will be referred to as ‘‘whole corneas.’’ Whole
corneas were maintained in culture no longer than 10
days before the start of experiments; during this time
they were stored either in Cornea Medium I without
Dextran T500 (Biochrom, Berlin, Germany) supplement-
ed with 2% fetal calf serum or in Cornea Medium II with
5% Dextran T500 (Biochrom) supplemented with 2%
fetal calf serum. In total this study used three samples of
this type.
2. Most samples were full-thickness cornea specimens
excised at corneal transplantation, obtained from Moor-
fields Eye Hospital, London, United Kingdom, with
informed consent. These will be referred to as ‘‘corneal
buttons.’’ In most cases corneal buttons derived from
patients undergoing penetrating keratoplasty for kerato-
conus. Specimen collection and arrangements for
consent were managed in accordance with the Declara-
tion of Helsinki and approved by the local research
ethics committee (ref. 09/H0721/6). Only specimens
with an apparently healthy endothelium were collected.
In total this study used 24 samples of this type.
Corneal samples were usually bisected with a diamond
blade before use. Whole corneas were bisected upon receipt
into the laboratory, whereas corneal buttons were bisected by
the surgeon immediately after excision. In all cases care was
taken when bisecting to minimize damage to the endothelium.
Upon receipt into the laboratory all corneas were maintained
at 378C in Cornea Medium I (no dextran, serum free). Whole
corneas were kept in 25 mL medium in T25 tissue culture
flasks, secured to float in the middle of the flask by a suture.
Corneal buttons were kept in 8 mL medium in six-well plates
with care taken to keep corneas lying endothelium-side up. In
both cases the medium was replaced weekly.
Transduction of Corneal Samples With Lentiviral
Vectors
For viral transduction of endothelium, human corneal speci-
mens were incubated in OptiMEM with concentrated virus
preparation for 4 hours at 378C. To achieve the highest possible
vector concentration, the volume of medium was minimized to
250 lL. In the case of larger samples (bisected whole corneas)
this was achieved by tilting the container at 458 to increase the
depth of the media so as to cover the sample. Multiplicity of
infection (MOI) was calculated as the number of infectious
particles per target cell during transduction. The total number of
endothelial cells per whole cornea was estimated to be 33 105.
Using 50 lL of a typical lentiviral vector preparation (titer: 2–33
108 infectious particles/mL) for one whole cornea resulted in an
MOI of ~40. For an excised corneal specimen, endothelial cell
number was estimated at 1.5 3 105 cells. To maximize the
potential effect size, the MOI in each experiment was the
maximum permitted by the viral titer available. After transduc-
tion corneal samples were cultured in Corneal Medium I for a
further 5 to 7 days before assessment.
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Reverse Transcription–Polymerase Chain Reaction
(RT-PCR)
Descemet’s membrane with corneal endothelium was peeled
off under an operating microscope and immediately lysed for
total RNA extraction by using a silica membrane/salt buffer
system (RNeasy Mini Kit, Qiagen, Hilden, Germany). For each
experiment, equal amounts of RNA were immediately reverse
transcribed into cDNA with the QuantiTect Reverse Transcrip-
tion Kit (Qiagen) following the manufacturer’s directions.
Primers listed in Supplementary Table S1 were used for
standard qPCR reactions with a dark quencher dye (Roche,
Basel, Switzerland). The PCR was run on an ABI Prism 7900HT
Fast Real-time Sequence Detection System (Applied Biosys-
tems, Waltham, MA, USA) using 10 to 70 ng of cDNA. Three
identical replicates were run for each sample, and the averaged
CT value was used for relative quantification using the
comparative CT method against 18s rRNA as reference gene
(DDCT method). REST software was used for qPCR analysis
(Relative Expression Software Tool, REST 2009, version
2.0.13).
Immunohistochemistry
Corneal samples were washed in PBS; fixed in 2% paraformal-
dehyde in PBS, pH 7.4, for 15 minutes; permeabilized with
0.2% Triton X-100 for 8 minutes; and blocked in 2% normal
goat serum, 2% fetal calf serum in PBS for 1 hour, all at room
temperature. Primary antibody was diluted in blocking
solution and incubated with the sample for 2 hours at room
temperature or overnight at 48C (anti–ZO-1 and anti-ZONAB,
Invitrogen; anti-Ki67, Sigma-Aldrich, Gillingham, UK). After
washing twice in PBS, sample was incubated with secondary
antibody (Alexa Fluor Secondary Antibodies; Invitrogen)
diluted 1:500 in block solution (1 hour at room temperature).
For flat-mounting, four radial cuts were made to flatten corneal
samples. They were attached to a glass microscopic slide
endothelium-side up, using cyanoacrylate glue; submerged in
fluorescent mounting medium (Agilent, Santa Clara, CA, USA);
and covered with a glass coverslip, using pressure-sensitive
adhesive as a spacer. Pressure was applied to flatten
Descemet’s membrane folds. Specimens were imaged by using
an upright confocal laser-scanning microscope (Leica TCS SPE
DM5500 Q; Leica Mirosystems, Wetzlar, Germany) with the
manufacturer’s software (Leica LAS AF, version 2.4.1).
ECD Assessment
Corneal ECD was quantified in flat-mounts, with the endothe-
lium en face, stained with 4 0,6-diamidino-2-phenylindole
(DAPI) by counting nuclei in micrographs obtained on the
confocal laser scanning microscope, with a defined image size
of 2753 275 lm (~0.076 mm2). The focus plane was chosen
so as to only image endothelial nuclei by adjusting aperture and
laser power. In some highly irregular endothelial surfaces, a z-
stack of approximately five images was overlaid. At least six
images were taken per sample, scanning through the flat-
mount in a standardized method. A distance of at least one
microscope field of view was left between micrographs
counted. An area of 0.5 mm from the cut edges of the cornea
was excluded. If the area of interest revealed gross damage to
the endothelium, it was also excluded. DAPI-positive nuclei
were counted manually by using ImageJ (version 1.46a; http://
rsbweb.nih.gov/ij/, provided in the public domain by the
National Institutes of Health, Bethesda, MD, USA). Counts of
the six or more images were averaged, comprising a minimum
total of 1000 to 1400 nuclei, and cell density was expressed as
cells/mm2. To obtain standardized and unbiased counts,
treatment and control samples were masked at the beginning
of the experiment by an independent observer. Equal numbers
of micrographs were counted for treatment and control
sample. Treatment and control sample of one cornea were
analyzed as pairs. If any cornea had apparent extensive
endothelial damage that prevented standardized imaging and
counting, both the treatment and the corresponding control
sample were excluded from further analysis.
Statistical Analysis
In all cases where statistics were applied, no more than two
groups or variables were compared and the threshold applied
for statistical significance was P  0.05. All tests used to
compare two groups were parametric two-tailed t-tests. All error
bars represent the standard error of the mean unless otherwise
stated. In cases where bisected corneas were exposed to two
independent treatments and compared as a group, the test
applied was a paired two-tailed t-test, with the two halves of the
same corneal sample being treated as pairs. In cases where
multiple measurements were performed in a single bisected
pair, the test applied was an unpaired two-tailed t-test. In cases
where correlation between two variables was assessed, a linear
regression analysis was performed and both the P value and
Pearson’s R were presented as measures of correlation.
FIGURE 1. Correlation between breakdown of tight junctions and
proliferation in human corneal endothelium. Flat-mount of full-
thickness cornea fixed within 1 hour of excision. Ki67-positive nuclei
can only be found in cells with reduced ZO-1 expression. (A)
Midperipheral endothelium, intact cell-cell contacts (ZO-1), no Ki67
staining. (B) Midperipheral endothelium, disrupted cell-cell boundaries
along Descemet’s membrane fold with Ki67-positive nuclei. (C, D)
Possible wounds to the endothelium associated with loose cell-cell
contacts and Ki67-positive nuclei.
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RESULTS
Correlation Between Loss of Contact Inhibition
and Proliferation in Endothelium
In normal human corneal endothelium, occasional signs of cell
proliferation can be observed in the form of cells that are
positive for Ki67 or bromodeoxyuridine (BrdU) staining, or in
the form of an occasional mitotic figure. To analyze any
correlation between these endogenous proliferating cells and
contact inhibition, we first examined normal human corneal
endothelium not maintained in long-term ex vivo culture.
Areas of obvious iatrogenic endothelial damage, such as cut
edges, were excluded from analysis. In total three samples (two
buttons and one whole cornea) were examined.
Immunostaining for ZO-1 in these samples revealed an
almost ubiquitously intact endothelial monolayer with Ki67-
negative nuclei, as shown in Figure 1A. However, very rarely,
small isolated areas displaying both an impaired/interrupted
pattern of ZO-1 staining and Ki67-positive nuclei were found
FIGURE 2. Downregulation of ZO-1 by LNT-shZO1. (A) qRT-PCR was performed in five different bisected corneal specimens (donors: 26–58 years of
age) after endothelial cell isolation 6 days post transduction. LNT-shZO1–transduced samples show a mean 51% 6 30% reduction in ZO-1 mRNA
compared to LNT-hrGFP–transduced control hemicorneas (P¼ 0.0191, paired t-test, error bars¼ 95% CI). (B) Example of a cornea excised from a
keratoconus patient 1 week after transduction. Reduced ZO-1 immunostaining (red) is seen in the LNT-shZO1–transduced half, while the
endothelial layer remains intact. Normal ZO-1 staining is seen in the control half transduced with LNT-hrGFP.
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(Figs. 1B, 1C), indicating a disruption of tight junctions and
cell-cell contact. These regions of loosened contact inhibition
appeared to correspond to folds in Descemet’s membrane or
areas of possible damage and appeared more common in the
periphery of the sample (Fig. 1D) than in the central or
midperipheral regions.
Effect of Knockdown of ZO-1 Upon ECD
To disrupt tight junctions, we first sought to downregulate ZO-
1 mRNA by using a lentiviral vector (LNT-shZO1) expressing an
shRNA against ZO-1 that has been previously shown to
effectively reduce ZO-1 protein levels in the human non-
transformed mammary epithelial cell line MCF-10A.25 The
effect of lentivirus-mediated downregulation of ZO-1 mRNA on
human corneal endothelium was assessed by quantitative RT-
PCR. Five corneal samples, whole corneas (32), or corneal
buttons (33) were bisected and transduced with either LNT-
shZO1 or LNT-hrGFP as control, at an MOI of ~40 for 4 hours.
After 6 days there was a 51% 6 30% (mean 6 SD) reduction of
ZO-1 mRNA in LNT-shZO1–transduced cells in comparison
with LNT-hrGFP–transduced controls (two-tailed paired t-test,
P ¼ 0.0191) (Fig. 2A). Endothelium transduced with LNT-
shZO1 also revealed no obvious changes in the integrity of the
monolayer, as visualized by ZO-1 immunohistochemistry on
flat-mounts (n ¼ 2). A representative example area of a
keratoconus specimen (28-year-old male patient) is shown in
Figure 2B. Five days after transduction, the half transduced
with LNT-shZO1 displayed uniformly reduced immunostaining
for ZO-1 in comparison with an LNT-hrGFP–transduced
control.
ECD was the principal outcome measure for ZO-1
downregulation in situ. In total, 10 corneal buttons (age range,
17–81 years) were analyzed for ECD. Each was bisected and
half was transduced with either LNT-shZO1 or LNT-hrGFP at an
MOI of ~50 to 100 for 4 hours, the latter acting as a control for
both transduction of and variation in initial ECD. Ex vivo
culture time was 7 days. Visualization of GFP in the LNT-
hrGFP–transduced samples allowed an approximate assess-
ment of transduction efficacy, estimated as ranging between
30% and 60%. The monolayer remained intact at the end of the
experiment, as verified by f-actin (phalloidin) staining with
DAPI nuclear counterstain. Representative immunofluores-
cence micrographs are shown in Figure 3A. Assessment of
ECD (six 0.076-mm2 areas per sample, Fig. 3B) revealed that
when analyzed individually, transduction by LNT-shZO1
resulted in a significant increase in ECD in 5 of 10 samples.
When analyzed as a whole there was an average ECD increase
of 18% within the group, but this did not reach significance (P
¼ 0.2029, two-tailed paired t-test) (Fig. 3C).
Proliferative Effect of LNT-shZO1 Correlates With
ECD but Not With Donor Age
We next assessed whether the observed increases in ECD
induced by LNT-shZO1 correlated with either the age or the
cell density of the control sample. Analyzing the same cohort
of 10 samples (age range, 17–81 years) we found no significant
correlation between donor age and ECD (Fig. 4A) and no
significant correlation between donor age and the change in
ECD induced by LNT-shZO1 (Fig. 4B). However, a significant
negative correlation (P¼ 0.01) was found between the change
in ECD induced by LNT-shZO1 and the ECD in LNT-hrGFP–
treated controls (Fig. 4C). From these findings we split our
cohort of 10 into two equal groups on the basis of control ECD
and reanalyzed for the proliferative effect of LNT-shZO1. The
high ECD group was not responsive to LNT-shZO1 (P¼ 0.803)
(Fig. 4D), but in the low ECD group there was a significant
average increase of 31% (P ¼ 0.042, two-tailed paired t-test)
(Fig. 4E). These results suggest that the initial ECD of the donor
cornea is the critical factor determining the proliferating effect
of LNT-shZO1, and that this factor may be more important than
age.
Effect of Overexpression of ZONAB Upon ECD
ZO-1 regulates proliferation by sequestering and thereby
inhibiting the activity of ZONAB, a transcription factor. Thus,
a complementary approach to downregulating ZO-1 would be
overexpression of ZONAB. We therefore examined the effect of
transducing the endothelium with a lentiviral vector express-
ing ZONAB (LNT-ZONAB).26 Corneal buttons from nine
patients aged between 21 and 33 years were bisected and
each half transduced with either LNT-ZONAB or LNT-hrGFP at
an MOI of ~50 to 100 for 4 hours. Specimens were maintained
FIGURE 3. Effect of downregulation of ZO-1 in human corneal
endothelium ex vivo. (A) Integrity of the endothelial cell monolayer
assessed 7 days post vector transduction by f-actin and DAPI staining of
corneal flat mounts. Transgene expression (GFP) is visible in the
control sample. Scale bar: 250 lm. (B) Effect of LNT-shZO1 upon ECD
in a single corneal sample. ECD quantified in seven micrographs (area
of each: 0.076 mm2) per hemicornea and calculated as cells/mm2.
Sample shown derives from a 20-year-old keratoconus patient and
shows a 30% increase in ECD (P¼0.0036, unpaired t-test). (C) Effect of
LNT-shZO1 upon ECD across all 10 corneal samples (donor age range,
17 to 81 years). No significant change in ECD was induced by LNT-
shZO1 (P ¼ 0.2029, paired t-test). Red line: Mean data. Black lines:
Individual samples with significant (P  0.05) changes in ECD. Gray
lines: Samples in which no such difference was found. Unpaired t-tests.
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in ex vivo culture for 7 days. Four of the samples were analyzed
by RT-PCR and confirmed overexpression of ZONAB (Fig. 5B).
The remaining five samples were immunostained for ZONAB to
verify transgene overexpression, and f-actin to assess cell
monolayer integrity (Fig. 5A). Vector-mediated ZONAB was
also shown to correlate and colocalize with Ki67 activation
(Supplementary Fig. S2). These samples were also analyzed for
changes in ECD resulting from transduction with LNT-ZONAB
over at least six areas per sample (Fig. 5C). Following LNT-
ZONAB transduction, all five samples displayed a significant
increase in ECD when compared with controls (Fig. 5D). The
overall mean increase in ECD was 26% (P¼ 0.0047, two-tailed
paired t-test), with a maximum increase of 33%.
DISCUSSION
Adult human corneal endothelium is subject to strong
inhibition of cell proliferation at a molecular level. Contact
inhibition, one molecular axis of which being the ZO-1/ZONAB
pathway, is recognized to have the strongest inhibitory
effect.18 Mechanical release from contact inhibition is the
basic principle used to generate a primary cell culture of nearly
all cells and can be applied to the culture of endothelial cells,
which then proliferate, albeit slowly, in vitro. By confocal
microscopy of healthy corneal endothelium, we have shown
disruption in ZO-1 staining to be associated with Ki67
positivity, further confirming the close correlation between
the breakdown of cell-cell contacts and proliferation. The
observation of such a loss of intercellular contact in a normal
cornea so shortly after excision suggests that in human corneal
endothelium, breakdown of tight junctions can occur naturally
to allow cell cycle progression, and indeed there is some
evidence for such limited endothelial renewal in vivo.29 In
endothelium of eyes cultivated in the eye bank over the longer
term, we also observed BrdU uptake after endothelial
wounding, that is, mechanically disrupting cell-cell contacts
(Supplementary Fig. S3). Despite these observations, it is clear
that any inherent capability of the corneal endothelium to
regenerate by mitosis is insufficient to compensate natural age-
related endothelial cell loss, let alone the increased loss
occurring after corneal transplantation, surgery, or in disease
states. One possible reason for this might be that contact
inhibition continues to be maintained even during cell loss, as
even in endothelium with very low cell density cell-cell
contacts remain intact over many years, resulting in enlarged
cells.30–32 By overcoming contact inhibition at a molecular
level, we were able to induce endothelial cell proliferation and
thereby increase cell density.
One of the first reported studies involving disruption of
contact inhibition in eye bank corneas was undertaken by
Senoo et al.20 By depleting calcium with EDTA in the presence
of mitogens, they could induce Ki67-positive mitotic figures.
However, this approach does not increase overall cell density.21
Nakano et al.33 have achieved downregulation of connexin 43,
a component of gap junctions that is required for contact
inhibition, by using antisense oligodeoxynucleotides or small
interfering RNA, in an in vivo rat corneal scrape injury model.
This induced Ki67 upregulation even in unwounded rat
epithelium, but overall cell density was not assessed and
human samples were not tested.
This study is the first to show an increase in corneal ECD
after molecular breakdown of contact inhibition in human
corneal endothelium ex vivo. Both vectors used in this study
could generate significant increases in ECD of similar
magnitudes, although the effect of LNT-shZO1 only became
significant within a low ECD cohort. By contrast the ECD
increases mediated by LNT-ZONAB were significant across a
broader range of densities. This may imply that directly
increasing the levels of ZONAB is more effective than indirect
modulation of ZONAB levels through ZO-1. Indeed, our qPCR
analysis revealed ZO-1 knockdown to be variable, and it is
possible that both this and any inefficiencies in translating the
effect downstream via ZONAB translocation and CDK4
activation may be responsible for the more limited effect of
ZO-1 knockdown. It is also important to note that control ECD
is not directly equivalent to initial, untreated ECD. Control
samples were transduced by control vector (LNT-hrGFP) and
spent a week in organ culture and we cannot rule out any
deleterious effects of these interventions. However, any
resulting change in ECD is controlled for by sham treatment
and we would expect any such effect to be both mild and
relatively consistent. Control density can therefore be consid-
ered reasonably representative of the untreated density. These
observations validate our hypothesis, which was based upon
several studies that have established a correlation between
either ZO-1 downregulation or ZONAB upregulation and
proliferation.22,25,26 Our results confirm the role of the ZO-1/
ZONAB pathway to be a significant molecular basis of contact
inhibition in the corneal endothelium. This study focused upon
the most clinically relevant endpoint, ECD, as its outcome
measure and did not further examine the downstream effects
FIGURE 4. Effect of LNT-shZO1 in relation to donor age and control ECD. (A) CEC density in control condition (LNT-hrGFP) correlated with age of
donor for all samples. No significant correlation. Pearson’s R¼0.24, P¼0.51. (B) Responsiveness to LNT-shZO1, measured as ratio between ECD in
LNT-shZO1– and LNT-hrGFP–treated halves, correlated with age of donor for all samples. No significant correlation. Pearson’s R¼0.17, P¼ 0.63.
(C) Responsiveness to LNT-shZO1, measured as ratio between ECD in LNT-shZO1– and LNT-hrGFP–treated halves, correlated with ECD of control
half. Significant negative correlation. Pearson’s R¼0.76, P ¼ 0.01. (D) Effect of LNT-shZO1 upon ECD across the five corneal samples with the
highest control ECD. No significant change in ECD was induced by LNT-shZO1 (P¼ 0.803, paired t-test). (E) Effect of LNT-shZO1 upon ECD across
the five corneal samples with the lowest control ECD. A significant mean increase in ECD of 31% was induced by LNT-shZO1 (P¼ 0.042, paired t-
test). Red line: Mean data. Black lines: Individual samples with significant (P  0.05) changes in ECD. Gray lines: Samples in which no such
difference was found. Unpaired t-tests.
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of ZO-1/ZONAB modulation. However, Sourisseau et al.25 have
shown that within the mammary epithelial cell line MCF-10A,
transcription of Cyclin D1 (a key regulator of G1/S-phase
transition) and PCNA (a crucial component of the DNA
replication machinery) are both directly regulated by ZONAB
at the transcriptional level.
Previous studies attempting to mediate cell cycle modula-
tion within corneal endothelial cells have observed that the
proliferative response of the corneal endothelium is dependent
on the donor age.34 We did not observe such an effect in our
LNT-shZO1 cohort, nor did we observe any correlation
between donor age and ECD. This is probably because our
cohort was relatively small. Irrespective of age, however, we
did observe a strong negative correlation between responsive-
ness to LNT-shZO1 and ECD. This finding underpins the
importance of contact inhibition in corneal endothelium. It
would appear that in low-density endothelium, where contact
inhibition is reduced, there is space for the cells to divide and
they are thus able to replicate in response to ZO-1 modulation.
In dense endothelium, stronger contact inhibition prevents this
response. It should also be noted that in low-ECD samples the
vector MOI would be proportionally increased and it is
possible that this may drive a stronger, dosage-driven response.
However, given that the MOI in all cases was set relatively high
we would not expect this to be the primary factor determining
the proliferative response.
Unfortunately, owing to the sample size, we were unable to
draw any conclusions with regard to the effect of age on
responsiveness to treatment. It is possible that the lower ECD
more generally associated with older donors might render such
a cornea more responsive to ZO-1 modulation. However, it is
possible that senescence of the endothelial cell population
might counteract this. The ability of endothelial cells to be
established in culture is reduced with donor age and the
kinetics of cell cycle entry is different in young and old cells.35
However, any age-related decrease in proliferative capacity is
not caused by replicative senescence, that is, the shortening of
telomeres with age. Telomere length remains constant over the
lifetime of the endothelium.36,37 Instead it has been proposed
that nuclear DNA damage from oxidative stress is the main
reason why some older cells are incapable of undergoing a full
cell cycle.38 Further studies are required to establish the
capacity of older endothelial cells to respond to the modulation
of contact inhibition.
In conclusion, we demonstrated that knockdown of ZO-1
expression and overexpression of ZONAB is possible in human
corneal endothelium ex vivo. Harmful effects on the endothe-
lium were not evident in the samples tested. The modulation in
expression of ZO-1 and ZONAB was associated with approx-
imately a 30% increase in cell density and we found some
evidence to suggest that this approach was less effective in
corneas from donors older than 70 years. Although the
increase seems relatively modest, this would be sufficient to
rescue a substantial number of donor corneas that would
otherwise be discarded owing to ECD below 2000 cells/mm2,
the standard applied in eye banks. Changes in ECD might be
increased further if cell transduction were more efficient than
the ~30% to 60% observed in this study, due to changes in
vector properties or design. Moreover, we have not investigat-
ed a dual approach in which both ZO-1 and ZONAB expression
are modulated in the same specimens by exposure to both
vectors. The observation that none of the treated corneas
reached an ECD > 3000 cells/mm2 (the density found in
humans at birth) might indicate that intrinsic mechanisms of
contact inhibition are strong enough to prevent any uncon-
trolled proliferation above this density level.
Further work to investigate the safety of ZO-1 and ZONAB
modulation and testing of endothelium function in corneas
modified ex vivo will be required before any potential clinical
application. However, with appropriate safety measures in
place, such as transient viral gene transfer mediated by a
nonintegrating lentiviral vector,39 this approach may become a
useful method to improve the quality of corneas for
transplantation.
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FIGURE 5. Effect of overexpression of ZONAB in human corneal
endothelium ex vivo. (A) Representative immunofluorescence micro-
graphs showing the integrity of the endothelial cell monolayer as
assessed by f-actin and DAPI staining of corneal flat mounts, and
transgene expression of ZONAB or GFP after 7 days. (B) qRT-PCR was
performed in four bisected corneal specimens after endothelial cell
isolation 6 days post transduction. LNT-ZONAB–transduced samples
show a more than 200-fold overexpression of ZONAB mRNA compared
to untransduced controls. (C) Effect of LNT-ZONAB upon ECD in a
single corneal sample. ECD quantified in seven micrographs (area of
each: 0.076 mm2) per hemicornea, calculated as cells/mm2. Sample
shown derives from a 31-year-old keratoconus patient and shows a 25%
increase in ECD (P ¼ 0.015, unpaired t-test). (D) Effect of LNT-shZO1
upon ECD across five corneal samples (donor age range, 21 to 32
years). A significant mean increase in ECD of 26% was induced by LNT-
ZONAB (P ¼ 0.0047, paired t-test). Mean data are represented by the
red line. All individual samples (black lines) also show significant
increases in ECD (P  0.05, unpaired t-tests).
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